Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This prospective controlled randomized open-label clinical trial is designed to determine the
optimal eradication rate of rabeprazole based sequential-concommitant hybrid therapies for
adults infected with Helicobacter pylori in Eastern Taiwan. Enrolled patients will receive 3,
5 or 7 days of pre-concommitant (sequential part) treatment with rabeprazole + amoxicillin,
then 7 days of concommitant treatment with rabeprazole + amoxicillin + clarithromycin +
metronidazole.